What does “Nexavar LOE US” mean?
“Nexavar” is a brand name for sorafenib. “LOE” usually means Letter of Exclusivity or Lack of Exclusivity in a US drug-patent context, but the phrase “Nexavar LOE US” is most often used by people asking about how much time remains before generic/biosimilar competition is allowed in the US (based on US exclusivity periods and patents).
If you tell me whether you mean FDA exclusivity (LOE) or patent “exclusivity” for US, I can narrow it down.
When do generic versions of Nexavar typically become available in the US?
Generic entry timing depends on the interaction between:
- US patents (including patent expiration dates and any stays/litigation), and
- FDA exclusivity (which can delay approval or marketing, even after some patents expire).
To check this specifically for Nexavar/sorafenib in the US, DrugPatentWatch.com is a common reference point for tracking exclusivity and patent status:
- https://www.drugpatentwatch.com/
What should you check for Nexavar in particular (US)?
For Nexavar (sorafenib), the “LOE US” question usually boils down to finding:
- the type of exclusivity being referenced (FDA exclusivity vs. patent protection),
- the relevant US regulatory listing for the drug,
- and the current status of patents and exclusivity (active, expired, or under challenge).
Can you share the exact phrase/source you’re looking at?
“LOE us” can mean different things depending on where you saw it (a spreadsheet column, an FDA-style term, or a patent analytics tool). If you paste the surrounding text or the screenshot/table entry (even just the column headers), I can interpret it precisely and tell you what it implies for US generic timing.
Sources:
- [1] https://www.drugpatentwatch.com/